Actively Recruiting
Continous Positive Airway Pressure (CPAP) Support for Acute Hypoxemic Respiratory Failure in Burkina Faso
Led by Université NAZI BONI · Updated on 2025-07-28
240
Participants Needed
4
Research Sites
32 weeks
Total Duration
On this page
Sponsors
U
Université NAZI BONI
Lead Sponsor
A
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsor
AI-Summary
What this Trial Is About
Acute respiratory failure (ARF) is a frequent medical emergency, involving high costs for health organizations and patients who often require intensive care and respiratory assistance. According to an international study, 61% of hypoxemic patients in intensive care receive invasive ventilation \[3\]. Invasive mechanical ventilation is often unavailable in low-income countries and non-invasive ventilatory supports such as continuous positive airway pressure (CPAP) and high-flow oxygen therapy (HFO) were very useful during the COVID-19 pandemic. They reduced the rate of intubation and ICU admissions. In addition, CPAP can be used without a ventilator, no electricity is required. So, it could be a support of choice in low-income countries. Used of Boussignac-type CPAP could potentially reduce the recourse to intubation in patients with acute hypoxemic respiratory failure in a context where access to invasive ventilation remains very limited.
CONDITIONS
Official Title
Continous Positive Airway Pressure (CPAP) Support for Acute Hypoxemic Respiratory Failure in Burkina Faso
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years and older
- Acute respiratory distress with a respiratory rate of 25 breaths per minute or higher
- Need for more than 6 liters of oxygen to keep oxygen saturation at or above 92%
You will not qualify if you...
- Pregnant or breastfeeding women
- Persons deprived of their liberty
- Exacerbation of asthma, chronic obstructive pulmonary disease, or other chronic respiratory diseases
- Moderate to large undrained pleural effusion
- Contraindications to CPAP such as patient refusal, undrained pneumothorax, chest injury, repeated or large vomiting, upper gastrointestinal bleeding, craniofacial trauma, severe upper airway obstruction, or tetraplegia in the initial phase
- Cardiac arrest, severe arrhythmias, or shock requiring vasopressors
- Altered consciousness (Glasgow Coma Scale score below 13), repeated seizures, or status epilepticus
- Medical decision to limit treatment (no intubation or ICU admission)
- Refusal to participate or participation in another interventional respiratory study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Centre Hospitalier Universitaire Souro Sanou
Bobo-Dioulasso, Houet, Burkina Faso, 01 BP 676
Actively Recruiting
2
CHU Yalgado Ouedraogo
Ouagadougou, Kadiogo, Burkina Faso, 03 BP 702250311655
Not Yet Recruiting
3
CHU Tengandogo
Ouagadougou, Kadiogo, Burkina Faso, 03 BP 7067
Not Yet Recruiting
4
CHU Bogodogo
Ouagadougou, Kadiogo, Burkina Faso, 14 BP 371
Not Yet Recruiting
Research Team
I
Ismael Guibla, doctor
CONTACT
I
Ibrahim Alain Traore, professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here